Candida glabrata fungaemia in intensive care units

Clinical Microbiology and Infection

Volumn 14, Issue 2, 2008, Pages 136-140

  Ruan, S Y ^a   Lee, L N ^a   Jerng, J S ^a   Yu, C J ^a   Hsueh, P R ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Candida glabrata; Epidemiology; Fungaemia; Intensive care units; Mortality; Treatment outcome

Indexed keywords

AMPHOTERICIN B; CASPOFUNGIN; FLUCONAZOLE;

ABDOMINAL SURGERY; ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; CANDIDA GLABRATA; CANDIDEMIA; CHEMOTHERAPY; CLINICAL ARTICLE; CRITICALLY ILL PATIENT; DRUG EXPOSURE; FEMALE; FUNGEMIA; HUMAN; INTENSIVE CARE UNIT; INTRAVASCULAR CATHETER; MALE; MORTALITY; NEUTROPENIA; PARENTERAL NUTRITION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SURVIVAL RATE; TREATMENT OUTCOME;

CANDIDA ALBICANS; CANDIDA GLABRATA;

EID: 38049075818     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2007.01892.x     Document Type: Article

References (25)

1. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: Analysis of 24179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004; 39: 309-317.
2. Bassetti M, Righi E, Costa A et al. Epidemiological trends in nosocomial candidemia in intensive care. BMC Infect Dis 2006; 6: 21-25.
3. AbiSaid D, Anaissie E, Uzun O, Raad I, Pinzcowski H, Vartivarian S. The epidemiology of hematogenous candidiasis caused by different Candida species. Clin Infect Dis 1997; 24: 1122-1128.
4. Trick WE, Fridkin SK, Edwards JR, Hajjeh RA, Gaynes RP. Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999. Clin Infect Dis 2002; 35: 627-630.
5. Anaissie EJ, McGinnis MR, Pfaller MA. Clinical mycology, 1st edn. Philadelphia: Churchill Livingstone, 2003.
6. Fidel PL, Vazquez JA, Sobel JD. Candida glabrata: Review of epidemiology, pathogenesis, and clinical disease with comparison to Candida albicans. Clin Microbiol Rev 1999; 12: 80-96.
7. Rangel-Frausto MS, Wiblin T, Blumberg HM et al. National Epidemiology of Mycoses Survey (NEMIS): Variations in rates of bloodstream infections due to Candida species in seven surgical intensive care units and six neonatal intensive care units. Clin Infect Dis 1999; 29: 253-258.
8. Voss A, le Noble JL, Verduyn Lunel FM, Foudraine NA, Meis JF. Candidemia in intensive care unit patients: Risk factors for mortality. Infection 1997; 25: 8-11.
9. Ostrosky-Zeichner L, Pappas PG. Invasive candidiasis in the intensive care unit. Crit Care Med 2006; 34: 857-863.
10. Eggimann P, Garbino J, Pittet D. Epidemiology of Candida species infections in critically ill non-immunosuppressed patients. Lancet Infect Dis 2003; 3: 685-702.
11. National Committee for Clinical Laboratory Standards. Reference method for broth microdilution antifungal susceptibility testing of yeasts, approved standard M27-A2. Wayne, PA: National Committee for Clinical Laboratory Standards, 2002.
12. Leone M, Albanese J, Antonini F, Michel-Nguyen A, Blanc-Bimar MC, Martin C. Long-term epidemiological survey of Candida species: Comparison of isolates found in an intensive care unit and in conventional wards. J Hosp Infect 2003; 55: 169-174.
13. Nucci M, Anaissie E. Revisiting the source of candidemia: Skin or gut? Clin Infect Dis 2001; 33: 1959-1967.
14. Bodey GP, Mardani M, Hanna HA et al. The epidemiology of Candida glabrata and Candida albicans fungemia in immunocompromised patients with cancer. Am J Med 2002; 112: 380-385.
15. Wingard JR, Merz WG, Rinaldi MG, Johnson TR, Karp JE, Saral R. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med 1991; 325: 1274-1277.
16. Samra Z, Yardeni M, Peled N, Bishara J. Species distribution and antifungal susceptibility of Candida bloodstream isolates in a tertiary medical center in Israel. Eur J Clin Microbiol Infect Dis 2005; 24: 592-595.
17. Pfaller MA, Diekema DJ. Twelve years of fluconazole in clinical practice: Global trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida. Clin Microbiol Infect 2004; 10 (suppl 1): 11-23.
18. da Matta DA, de Almeida LP, Machado AM et al. Antifungal susceptibility of 1000 Candida bloodstream isolates to 5 antifungal drugs: Results of a multicenter study conducted in Sao Paulo, Brazil, 1995-2003. Diagn Microbiol Infect Dis 2007; 57: 399-404.
19. Hsueh PR, Lau YJ, Chuang YC et al. Antifungal susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species from Taiwan: Surveillance of multicenter antimicrobial resistance in Taiwan program data from 2003. Antimicrob Agents Chemother 2005; 49: 512-517.
20. Phillips P, Shafran S, Garber G et al. Multicenter randomized trial of fluconazole versus amphotericinB for treatment of candidemia in non-neutropenic patients. Canadian Candidemia Study Group. Eur J Clin Microbiol Infect Dis 1997; 16: 337-345.
21. Kontoyiannis DP, Bodey GP, Mantzoros CS. Fluconazole vs. amphotericinB for the management of candidaemia in adults: A meta-analysis. Mycoses 2001; 44: 125-135.
22. Rex JH, Bennett JE, Sugar AM et al. A randomized trial comparing fluconazole with amphotericin-B for the treatment of candidemia in patients without neutropenia. N Engl J Med 1994; 331: 1325-1330.
23. Pappas PG, Rex JH, Lee J et al. A prospective observational study of candidemia: Epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis 2003; 37: 634-643.
24. Pappas PG, Rex JH, Sobel JD et al. Guidelines for treatment of candidiasis. Clin Infect Dis 2004; 38: 161-189.
25. Spellberg BJ, Filler SG, Edwards JE. Current treatment strategies for disseminated candidiasis. Clin Infect Dis 2006; 42: 244-251.